Broad-Spectrum
Ebola virus
GS-441524
GS-5734
HSAEC1-KT
Huh7 cells
NCI-H358 cells
Nipah virus
ODBG
ODBG-P-RVn
SARS-CoV-2
Vero E6 cells
antiviral agents
filovirus
hemorrhagic fever virus
henipavirus
human small airway epithelial cells
human telomerase reverse-transcriptase (hTERT)-immortalized microvascular endothelial cells (TIME)
lipid prodrugs
paramyxovirus
remdesivir
remdesivir nucleoside
respiratory viruses
Journal
Microbiology spectrum
ISSN: 2165-0497
Titre abrégé: Microbiol Spectr
Pays: United States
ID NLM: 101634614
Informations de publication
Date de publication:
22 12 2021
22 12 2021
Historique:
pubmed:
25
11
2021
medline:
6
1
2022
entrez:
24
11
2021
Statut:
ppublish
Résumé
The necessity for intravenous administration of remdesivir confines its utility for treatment of coronavirus disease 2019 (COVID-19) to hospitalized patients. We evaluated the broad-spectrum antiviral activity of ODBG-P-RVn, an orally available, lipid-modified monophosphate prodrug of the remdesivir parent nucleoside (GS-441524), against viruses that cause diseases of human public health concern, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). ODBG-P-RVn showed 20-fold greater antiviral activity than GS-441524 and had activity nearly equivalent to that of remdesivir in primary-like human small airway epithelial cells. Our results warrant
Identifiants
pubmed: 34817209
doi: 10.1128/Spectrum.01537-21
pmc: PMC8612139
doi:
Substances chimiques
Antiviral Agents
0
Glyceryl Ethers
0
Lipids
0
Nucleosides
0
ODBG-P-RVn
0
Prodrugs
0
GS-441524
1BQK176DT6
remdesivir
3QKI37EEHE
Adenosine Monophosphate
415SHH325A
Adenosine
K72T3FS567
Alanine
OF5P57N2ZX
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0153721Subventions
Organisme : NIAID NIH HHS
ID : R01 AI131424
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI161348
Pays : United States
Organisme : HHS | Centers for Disease Control and Prevention (CDC)
ID : Core funding
Organisme : HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
ID : RO1-AI131424
Commentaires et corrections
Type : UpdateOf
Références
Clin Microbiol Rev. 2020 Oct 14;34(1):
pubmed: 33055231
Exp Cell Res. 2002 Feb 1;273(1):21-33
pubmed: 11795943
Sci Rep. 2017 Mar 06;7:43395
pubmed: 28262699
J Med Chem. 2021 Apr 22;64(8):5001-5017
pubmed: 33835812
J Med Chem. 2017 Mar 9;60(5):1648-1661
pubmed: 28124907
J Antimicrob Chemother. 2020 Oct 1;75(10):2977-2980
pubmed: 32607555
PLoS Negl Trop Dis. 2018 Mar 9;12(3):e0006326
pubmed: 29522528
Cancer Res. 2004 Dec 15;64(24):9027-34
pubmed: 15604268
Antiviral Res. 2009 May;82(2):A84-98
pubmed: 19425198
J Infect Dis. 2020 May 11;221(Supplement_4):S480-S492
pubmed: 32037447
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
J Feline Med Surg. 2019 Apr;21(4):271-281
pubmed: 30755068
Emerg Microbes Infect. 2021 Dec;10(1):481-492
pubmed: 33691601
Vet Microbiol. 2018 Jun;219:226-233
pubmed: 29778200
Antiviral Res. 2018 May;153:101-113
pubmed: 29601894
Antimicrob Agents Chemother. 2021 Sep 17;65(10):e0115521
pubmed: 34310217
J Med Chem. 2022 Feb 24;65(4):2785-2793
pubmed: 33523654
Clin Transl Sci. 2020 Sep;13(5):896-906
pubmed: 32589775
Cell Host Microbe. 2020 May 13;27(5):841-848.e3
pubmed: 32289263
Nature. 2016 Mar 17;531(7594):381-5
pubmed: 26934220
Antiviral Res. 2007 Mar;73(3):212-8
pubmed: 17123638